TABLE 1.

PK parameters obtained by noncompartmental analysis after administration of different capreomycin formulations by different routesa

Treatment route (formulation)AUC0-t (μg·h/ml)CL_F (ml/h·kg)K (h−1)t1/2 (h)MRT (h)Cmax (μg/ml)Tmax (h)MAT (h)F0-t
i.v. (20 mg/kg; solution)49.29 ± 10.7120.42 ± 0.102,30.92 ± 0.1010.75 ± 0.0840.88 ± 0.09353.56 ± 3.9310.08 ± 0.0031.00 ± 0.001
i.m. (20 mg/kg; solution)58.20 ± 10.9810.35 ± 0.0630.68 ± 0.181,2,31.09 ± 0.303,41.44 ± 0.30232.33 ± 3.7520.36 ± 0.2810.44 ± 0.2021.20 ± 0.231
Insufflation
    14.5 mg/kg; powder16.95 ± 3.9430.54 ± 0.111,20.48 ± 0.132,31.53 ± 0.361,21.80 ± 0.1216.70 ± 1.2630.31 ± 0.121,20.80 ± 0.1210.54 ± 0.112
    7.2 mg/kg; powder8.20 ± 1.4540.52 ± 0.1020.45 ± 0.1131.68 ± 0.3711.72 ± 0.1813.34 ± 0.4940.38 ± 0.1410.72 ± 0.1810.59 ± 0.122
    1.4 mg/kg; powder1.15 ± 0.3650.67 ± 0.2510.71 ± 0.421,21.22 ± 0.562,31.01 ± 0.3130.92 ± 0.3850.5 ± 0.311b0.41 ± 0.142
  • a Data are averages ± standard deviations (n = 6 to 8). Numeric superscripts show the relative ranks of values (starting from the highest values). When the means are not significantly different, the same superscript is used.

  • b MAT could not be estimated for this low dose.